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ABSTRACT
Background Bedside lung ultrasound (LUS) is an 
affordable diagnostic tool that could contribute to 
identifying COVID-19 pneumonia. Different LUS protocols 
are currently used at the emergency department (ED) and 
there is a need to know their diagnostic accuracy.
Design A multicentre, prospective, observational study, 
to compare the diagnostic accuracy of three commonly 
used LUS protocols in identifying COVID-19 pneumonia at 
the ED.
Setting/patients Adult patients with suspected COVID-19 
at the ED, in whom we prospectively performed 12- zone 
LUS and SARS- CoV-2 reverse transcription PCR.
Measurements We assessed diagnostic accuracy for 
three different ultrasound protocols using both PCR and 
final diagnosis as a reference standard.
Results Between 19 March 2020 and 4 May 2020, 202 
patients were included. Sensitivity, specificity and negative 
predictive value compared with PCR for 12- zone LUS were 
91.4% (95% CI 84.4 to 96.0), 83.5% (95% CI 74.6 to 90.3) 
and 90.0% (95% CI 82.7 to 94.4). For 8- zone and 6- zone 
protocols, these results were 79.7 (95% CI 69.9 to 87.6), 
69.0% (95% CI 59.6 to 77.4) and 81.3% (95% CI 73.8 to 
87.0) versus 89.9% (95% CI 81.7 to 95.3), 57.5% (95% CI 
47.9 to 66.8) and 87.8% (95% CI 79.2 to 93.2). Negative 
likelihood ratios for 12, 8 and 6 zones were 0.1, 0.3 
and 0.2, respectively. Compared with the final diagnosis 
specificity increased to 83.5% (95% CI 74.6 to 90.3), 
78.4% (95% CI 68.8 to 86.1) and 65.0% (95% CI 54.6 
to 74.4), respectively, while the negative likelihood ratios 
were 0.1, 0.2 and 0.16.
Conclusion Identifying COVID-19 pneumonia at the ED 
can be aided by bedside LUS. The more efficient 6- zone 
protocol is an excellent screening tool, while the 12- zone 
protocol is more specific and gives a general impression 
on lung involvement.
Trial registration number NL8497.
INTRODUCTION
The COVID-19 pandemic hotspot has 
moved to less affluent societies with more 
pronounced socioeconomic disparities and 
limited medical resources.1 Infected individ-
uals need to be recognised and isolated to 
slow down the spread. The morbidity and 
mortality of COVID-19 are most frequently 
caused by pneumonia and acute respiratory 
failure with need for supportive medical 
care.2 3
SARS- CoV-2 reverse transcription PCR is the 
current gold standard for diagnosing COVID-
19. However, PCR has limited sensitivity in 
daily practice, test capacity is often insuffi-
cient, and turnaround time too long to be 
useful in the emergency department (ED).4 
To overcome these limitations, imaging to 
detect lung involvement has been advocated 
since this is fast and widely available. Unfortu-
nately, chest X- ray has a poor negative predic-
tive value.5 6 Although CT of the chest does 
have good diagnostic accuracy, it is not always 
available in resource constrained areas.5–9 
Moreover, an extra risk of cross contamina-
tion of healthcare personnel and patients 
comes along with both radiological tech-
niques. Also, the necessary cleaning proce-
dures are rather time consuming.10
Strengths and limitations of this study
 ► This study has prospectively compared the diagnos-
tic accuracy of three different lung ultrasound (LUS) 
protocols in diagnosing COVID-19 pneumonia in a 
multicentre setting.
 ► All study participants received a regular medical 
workup (history, physical examination and routine 
laboratory tests) and a bedside LUS at the emergen-
cy department.
 ► LUS findings were classified for the different pro-
tocols with prespecified criteria compatible with 
COVID-19 pneumonia.
 ► Two reference standards for COVID-19 were applied: 
a positive reverse transcription PCR test and multi-
disciplinary team of experts’ decision after excluding 
alternative diagnoses and blinded for LUS results.
 ► Only one physician performed the LUS per patient 
to minimise infection risk and to avoid unnecessary 
spending of scarce personal protection material.
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Lung ultrasound could contribute to identification of 
COVID-19 pneumonia and help guide patient manage-
ment.11–20 It has proven to reliably exclude COVID-19 
pneumonia with equal accuracy to CT of the chest.21–24 Its 
advantages include: speed, affordability, ease of use, avail-
ability in low resource situations (especially handheld 
devices) and reducing the risk of transmission by mini-
mising the need for patient transport. Cleaning proce-
dures are much easier especially when handheld devices 
are used.19 20 25
Since the emergence of COVID-19, different lung ultra-
sound protocols have been used. The current protocols 
in COVID-19 scan 6,19 8,23 26 1217 18 24 or 1413 15 sites on the 
thoracic surface. It is unclear which of these protocols is 
best used in COVID-19.
The 12 and 14 site strategies can be performed within 
10 min, while the 6 and 8 site strategies take 3 min at 
the most. In an overcrowded ED, scanning quickly is most 
desirable.
To the best of our knowledge, no studies comparing 
the diagnostic accuracy of different lung ultrasound 
protocols in pneumonia of any other aetiology have been 
conducted. The literature on acute heart failure at the 
ED27 and acute respiratory distress syndrome (ARDS) in 
the intensive care unit28 have shown that using less scan 
sites can be equally accurate.
In this real- life, multicentre, observational study, we, 
therefore assessed and compared the diagnostic accuracy 
of three commonly used bedside lung ultrasound proto-
cols in identifying COVID-19 at the ED.
METHODS
Study protocol
This multicentre, observational study was conducted at 
the EDs of three academic hospitals in the Netherlands 
(Radboud University Medical Centre, Nijmegen, and 
both locations of the Amsterdam University Medical 
Centers) between 19 March 2020 and 4 May 2020. This 
study was registered with the Dutch Trial Registry.
Patient and public involvement
There were no patients or public involved in the study 
protocol.
Design
All eligible patients were 18 years and older who visited the 
ED with suspected COVID-19. The COVID-19 case defini-
tion of the WHO and Dutch centre for disease control 
(RIVM) was used. This was initially defined as having 
either fever, malaise, myalgia and respiratory symptoms, 
and subsequently included gastrointestinal symptoms, 
loss of smell or taste, and unexplained delirium in the 
elderly.
Inclusion criteria were a SARS- CoV-2 PCR and verbal 
informed consent. Exclusion criteria were age under 18 
years, no verbal consent given.
All study participants received a regular medical workup 
(history, physical examination and routine laboratory 
tests) and a bedside lung ultrasound at the ED. If imaging 
of the thorax was deemed necessary by the treating physi-
cian, a CT of the chest was performed which was in accor-
dance with local clinical guidelines.
In patients with a high clinical suspicion but negative 
PCR, a diagnosis of COVID-19 still could be made by a 
multidisciplinary team (MDT) of experts after excluding 
alternative diagnoses. In all three participating hospi-
tals, it was routine care that the admitted patients were 
discussed daily in this MDT consisting of consultants in 
infectious disease, respiratory disease and microbiology. 
This panel reviewed all available clinical, laboratory, 
microbiological and CT data, and decided on the final 
diagnosis. The expert panel was blinded for the lung 
ultrasound findings during the course of the study.
Ultrasound methods
Bedside lung ultrasound was performed at the ED as 
an extension of the physical examination. Scans were 
performed or supervised by acute internal medicine physi-
cians who were certified in point- of- care ultrasound and 
had entrustable professional activity (EPA) level of 4–5. 
See online supplemental appendix for an explanation 
on EPA. All patients received a 12- zone ultrasound and 
the findings were classified for the different lung ultra-
sound protocols as described in the paragraphs below. 
The sonographers performing the lung ultrasound were 
blinded for the PCR and radiological results.
Handheld ultrasound systems (Iviz Sonosite and 
Butterfly IQ Butterfly) were mostly used with a lung 
pre- set (ie, settings amenable to the detection of B- line 
artefacts). In case handheld systems were not available 
a cart- based system was used (Sonosite) with an abdom-
inal preset with tissue harmonic imaging switched off and 
dynamic range put at the lowest level.
Twelve-zone method
Scanning was done in a lawn mower fashion with six 
scanning sites on each hemithorax: two anteriorly, two 
laterally and two posteriorly. See figure 1 for details on 
the scanning zones and technique. Images of the 12 
scanning zones are available in the online supplemental 
appendix. The ultrasound was assessed real- time as posi-
tive or negative for COVID-19. A scan was defined positive 
by the presence of sonographic abnormalities consistent 
with COVID-19 in two or more zones unilaterally, or 
one or more zones bilaterally (see online supplemental 
table 1:18 for typical sonographic findings in COVID-19 
pneumonia).
Six-points method (BLUE protocol)
This protocol is an acronym for bedside lung ultrasound 
in emergency (BLUE) and categorises the lung ultra-
sound findings into BLUE profiles.29 30 Three sites on each 
hemithorax are scanned: the upper BLUE point, lower 
BLUE point and the posterior lateral alveolar pulmonary 
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syndrome point (PLAPS). See figure 2 for details on the 
scanning zones. The BLUE profile was determined real 
time. Based on the features and distribution of COVID-19 
pneumonia, the following BLUE profiles were consid-
ered consistent with COVID-19 pneumonia:
 ► A- profile with bilateral PLAPS without pleural 
effusion.
 ► A/B- profile.
 ► B’-profile.
 ► C- profile.
Profiles that were deemed not in keeping with 
COVID-19 were:
 ► A- profile without PLAPS (asthma/Chronic Obstruc-
tive Pulmonary Disease, pulmonary embolism and 
non- pulmonary conditions).
 ► A- profile with unilateral PLAPS (lobar pneumonia).
 ► A- profile with bilateral PLAPS due to pleural effusion 
(heart failure).
 ► B- profile (heart failure).
Eight-points method
Scanning is done at four sites on each hemithorax: 
two anterior and two lateral. See figure 3 for details 
on the scanning zones. A positive scan was defined by 
the presence of at least one of the artefacts described 
(online supplemental table 1) in one or more zones 
bilaterally or two or more zones unilaterally.
Outcome
Sensitivity, specificity, diagnostic accuracy and predic-
tive values of three different lung ultrasound proto-
cols in COVID-19 were assessed against two reference 
standards: (serial) PCR (gold standard) and the final 
diagnosis.
Figure 1 Example is demonstrated by a volunteer. Scanning 
zones in the 12- zone method. Z1–Z6 are the six zones on 
each hemithorax together forming 12 zones. Anterior (A): 
Z1–Z2; lateral (B): Z3–Z4; posterior (C): Z5–Z6. Red- coloured 
lines depict the lawn mower technique. AAL, anterior axillary 
line; PAL, posterior axillary line.
Figure 2 Example is demonstrated by a volunteer. Scanning 
zones in the six- points method. Yellow symbols are the three 
points on each hemithorax together forming six points. Yellow 
triangle: upper BLUE point; yellow square: lower BLUE point; 
yellow star: PLAPS point. AAL, anterior axillary line; BLUE, 
bedside lung ultrasound in emergency; PAL, posterior axillary 
line; PLAPS, posterior lateral alveolar pleural syndrome.
Figure 3 Example is demonstrated by a volunteer. Scanning 
zones in the eight- points method. Z1–Z4 are the four zones 
on each hemithorax together forming eight zones. Anterior: 
Z1–Z2; lateral: Z3–Z4. AAL, anterior axillary line; PAL, 
posterior axillary line.
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Statistical analysis
No sample size calculation was performed. Normally 
distributed continuous variables are summarised by 
their mean and SD. Continuous variables that are 
not normally distributed are summarised by their 
median and IQR. Differences between patient groups 
were tested using the independent t- test for normally 
distributed outcomes and difference in means and 
95% CI were calculated. The widths of the intervals 
have not been adjusted for multiplicity, inferences 
drawn may, therefore, not be reproducible. Non- 
parametric Mann- Whitney U test was used to compare 
continuous outcomes that were not normally distrib-
uted between groups. Sensitivity and specificity of the 
different lung ultrasound protocols were compared 
using the McNemar test.
Analyses were performed in SPSS V.26. Data were anal-
ysed by the first four authors: BK, FS, AL and KA.
RESULTS
From 19 March 2020 until 4 May 2020, 202 patients with a 
suspicion of COVID-19 were included in our study. There 
were neither missing data, nor adverse events. See table 1 
for patient demographics and clinical characteristics.
The descriptive statistics of the lung ultrasound proto-
cols are given in tables 2 and 3.
The following diagnostic measures for the different 
protocols compared with PCR were found. For 12- zone 
ultrasound, we found a sensitivity of 91.4% (95% CI 84.4 
to 96.0), specificity of 83.5% (95% CI 74.6 to 90.3), nega-
tive predictive value of 90.0% (95% CI 82.7 to 94.4) and 
negative likelihood ratio of 0.1 (95% CI 0.05 to 0.2). For 
the 6- points protocol, we found a sensitivity of 89.9% 
(95% CI 81.7 to 95.3), specificity of 57.5% (95% CI 47.9 
to 66.8), negative predictive value of 87.8% (95% CI 79.2 
to 93.2) and negative likelihood ratio of 0.2 (95% CI 0.1 
to 0.3). For the 8- points method, we found a sensitivity 
79.7% (95% CI 69.9 to 87.6), specificity of 69.0% (95% 
CI 59.6 to 77.4), negative predictive value of 81.3% (95% 
CI 73.8 to 87.0) and negative likelihood ratio of 0.3 (95% 
CI 0.2 to 0.5).
We also calculated diagnostic measures compared with 
the final diagnosis decided by the medical expert panel. 
Ninety six patients with a final diagnosis of COVID-19 had 
a positive 12- zone lung ultrasound. The statistical results 
were as follows.
The 12- zone lung ultrasound protocol had a sensitivity 
of 91.4% (95% CI 84.4 to 96.0), specificity of 83.5% (95% 
CI 74.6 to 90.3), negative predictive value of 90.0% (95% 
CI 82.7 to 94.4) and negative likelihood ratio of 0.1 (95% 
CI 0.05 to 0.2). The 6- points protocol had a sensitivity of 
89.5 (95% CI 82.0 to 94.7), specificity of 65.0% (95% CI 




SARS- CoV-2 PCR 
positive N=89
SARS- CoV-2 PCR 
negative N=113 P value
Age, mean (SD) 62.4 (16.1) 62.6 (14.9) 62.3 (17.2) 0.281
Male, n (%) 117 (57.8) 53 (59.6) 64 (56.6) 0.336
Admission, n (%) 140 (69.3) 65 (73.0) 75 (66.4) 0.000
Admission Intensive Care, n (%) 10 (4.9) 8 (8.9) 2 (1.8) 0.000
30- day mortality, n (%) 15 (7.4) 6 (6.7) 9 (8.0) 0.467
In- hospital mortality, n (%) 10 (4.9) 5 (5.6) 5 (4.4) 0.018
Duration of symptoms days (SD) 6.8 (5.6) 7.4 (4.1) 6.2 (6.5) 0.001
Comorbidities, n (%)
  Asthma 12 (5.9) 4 (4.5) 8 (7.1) 0.113
  Chronic cardiovascular disease 44 (21.7) 18 (20.0) 26 (23.0) 0.301
  Chronic Obstructive Pulmonary Disease ( >2), 
n (%)
31 (15.3) 12 (13.3) 19 (16.8) 0.170
  Current malignancy 42 (20.7) 9 (10.0) 33 (29.2) 0.000
  Diabetes mellitus 35 (17.3) 21 (23.6) 14 (12.4) 0.000
Laboratory analysis on admission
  Positive blood culture, n (%) 12 (5.9) 1 (1.1) 11 (9.7) 0.798
  Modified early warning score mean (SD) 2.6 (1.9) 2.9 (1.9) 2.3 (1.8) 0.542
  Temperature (°C), mean (SD) 37.5 (1.2) 37.8 (1.0) 37.2 (1.3) 0.105
  Respiratory rate, mean (SD) 21.1 (7.0) 21.7 (7.4) 20.5 (6.6) 0.566
  Saturation levels (SD) 95.8 (3.2) 94.9 (3.5) 96.5 (2.8) 0.120
  Intubation, n (%) 10 (4.9) 8 (8.9) 2 (1.8) 0.000
  Oxygen therapy, n (%) 59 (29.1) 35 (38.9) 24 (22) 0.000
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54.6 to 74.4), negative predictive value of 85.1% (95% CI 
76.3 to 91.1) and negative likelihood ratio of 0.16 (95% 
CI 0.09 to 0.3). The 8- points method had a sensitivity of 
81.0% (95% CI 72.1 to 88.0), specificity of 78.4% (95% CI 
68.8 to 86.1), negative predictive value of 79.2% (95% CI 
71.7 to 85.1) and negative likelihood ratio of 0.2 (95% CI 
0.2 to 0.4). Comprehensive results are shown in table 2.
The inter- observer reliability of 12- zone lung ultra-
sound was excellent, with an intraclass correlation coeffi-
cient of 0.88 (95% CI 0.77 to 0.95).
Six patients had false negative results in the 12- zone 
scan and thus also in the 6- points and 8- points protocols. 
In four of these patients, ultrasound abnormalities were 
seen in one zone only. Therefore, the results were not 
compatible with the prespecified criteria for a positive 
ultrasound scan. In the remaining two patients, no abnor-
malities were seen at all.
Three patients had false negative results in the six- 
points protocol. One of these was falsely negative in the 
eight- points protocol too. All three false negative ultra-
sounds had abnormalities visualised in one zone only 
(eg, BLUE profile A with unilateral PLAPS or only one 
site in the eight- points protocol). As such, they were not 
in keeping with COVID-19 pneumonia. However, if the 
12- zone protocol was applied, all three ultrasounds were 
positive.
Eleven patients had a false negative ultrasound in 
the 8- points protocol but not in the 6- points or 12- zone 
protocol.
Twenty nine patients had a false positive ultrasound in 
the 12- zone protocol. Further analysis of these 29 scans 
showed that 22 ultrasounds were falsely positive in all 
three protocols, 6 recordings in the 12- zone protocol and 
1 other protocol (5/6 also in the 6- points protocol and 
1/6 also in the 8- points protocol) and 1 false positive scan 
in the 12- zone protocol only.
Twenty three patients had a false positive ultrasound 
in one or both of the six- points and eight- points proto-
cols but not in the 12- zone approach. Twelve scans were 
solely false positive in the six- points method and two scans 
were false positive in the eight- points method only. The 
remaining nine false positive ultrasounds were considered 
as such in both the six- points and eight- points protocols.
DISCUSSION
Screening
The findings in our study show that the 6- points protocol 
and the 12- zone approach can reliably and safely rule 
out COVID-19 pneumonia. Our study also shows that 
one must convert to a complete 12- zone ultrasound 
in case any abnormalities are seen in the six- points 
Table 2 Descriptive statistics of the three lung ultrasound protocols vs SARS- CoV-2 PCR
Diagnostic accuracy
6- points protocol vs SARS- 
CoV-2 PCR
8- points protocol vs SARS- 
CoV-2 PCR
12- zone protocol vs SARS- 
CoV-2 PCR
Sensitivity (%) (95% CI) 89.9 (81.7 to 95.3) 79.7 (69.9 to 87.6) 91.4 (84.4 to 96.0)
Specificity (%) (95% CI) 57.5 (47.9 to 66.8) 69.0 (59.6 to 77.4) 83.5 (74.6 to 90.3)
Positive likelihood ratio 2.1 (1.7 to 2.7) 2.6 (1.9 to 3.5) 5.5 (3.5 to 8.7)
Negative likelihood ratio 0.2 (0.1 to 0.3) 0.3 (0.2 to 0.5) 0.1 (0.05 to 0.2)
Positive predicive value (%) (95% 
CI)
62.5 (57.1 to 67.6) 67.0 (60.1 to 73.1) 85.7 (79.3 to 90.4)
Negative predictive value (%) 
(95% CI)
87.8 (79.2 to 93.2) 81.3 (73.8 to 87) 90.0 (82.7 to 94.4)
Accuracy (%) 71.8 (65.0 to 77.9) 73.8 (67.1 to 79.7) 87.6 (82.3 to 91.8)
Table 3 Descriptive statistics of the three lung ultrasound protocols vs final diagnosis
Diagnostic accuracy
6- points protocol vs final 
diagnosis
8- points protocol vs final 
diagnosis 12- zone vs final diagnosis
Sensitivity (%) (95% CI) 89.5 (82.0 to 94.7) 81.0 (72.1 to 88.0) 91.4 (84.4 to 96.0)
Specificity (%) (95% CI) 65.0 (54.6 to 74.4) 78.4 (68.8 to 86.1) 83.5 (74.6 to 90.3)
Positive likelihood ratio 2.6 (1.9 to 3.4) 3.7 (2.5 to 5.5) 5.6 (3.6 to 8.8)
Negative likelihood ratio 0.16 (0.09 to 0.3) 0.2 (0.2 to 0.4) 0.1 (0.05 to 0.2)
Positive predictive value (%) (95% 
CI)
73.4 (67.7 to 78.5) 80.2 (73.3 to 85.7) 85.7 (79.2 to 90.4)
Negative predictive value (%) 
(95% CI)
85.1 (76.3 to 91.1) 79.2 (71.7 to 85.1) 90.0 (82.7 to 94.4)
Accuracy (%) 77.7 (71.4 to 83.3) 79.7 (73.5 to 85.0) 87.6 (82.3 to 91.8)
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method. Application of this approach will minimise the 
chance of a false negative ultrasound in the six- points 
protocol.
In our study, the three false negatives in the six- 
points protocol had the BLUE- profile A with unilateral 
PLAPS, which is suggestive of lobar pneumonia.29 30 If 
the ultrasound examination was extended to a 12- zone 
scanning, all three scans would have been ruled in. On 
the contrary, the absence of any abnormality in the six- 
points protocol safely rules out COVID-19 pneumonia. 
In our study, this was shown by the excellent negative 
predictive values of the 12- zone and 6- points protocols. 
Importantly, patients who were COVID-19 positive with 
false negative results in the six- points protocol had no 
need for admission due to COVID-19- related symptoms.
Conversely, in our study, the eight- points scan-
ning method resulted in missing patients in whom 
supportive care was necessary. The lower sensitivity of 
this approach could be explained by the fact that scan-
ning of the posterior chest is omitted. In COVID-19 
pneumonia, abnormalities tend to originate inferior 
posterior. Our results indicate that zone six (named 
PLAPS in the BLUE protocol) should be examined to 
have a high negative predictive value.
Although scanning this zone can sometimes be chal-
lenging in immobile, obese and bedridden patients, a 
supine patient can still be examined by adduction of 
the arm across the midline and thereby exposing the 
back of the chest.
Diagnosing
The specificities of the lung ultrasound protocols in our 
study are substantially lower than found in the litera-
ture on pneumonia.29–34 For example, findings which 
we considered suggestive of COVID-19 pneumonia in 
the six- points and eight- points protocols were in fact 
compatible with lobar pneumonia, heart failure with 
pleural effusion, compression atelectasis or progression 
of intrapulmonary malignancy.
The suboptimal specificity of the six- points and eight- 
points protocol are inherent to their limited scanning 
area. COVID-19 pneumonia has a patchy and irregular 
distribution. In the six- points protocol, too few zones 
are scanned to have a good overview, which improves 
the specificity of lung ultrasound. Also, COVID-19 
pneumonia tends to begin inferior posterior, but this 
holds also true for pleural effusion and compression 
atelectasis. In the eight- points protocol, there is no 
visualisation of this area and thus valuable information 
which increases specificity is missed. In summary, our 
study has shown that a 12- zone lung ultrasound yields 
the highest specificity to diagnose COVID-19 pneu-
monia compared with the six- points and eight- points 
protocols.
Nevertheless, the limited specificity of lung ultrasound 
is inherent to COVID-19 pneumonia, which does not 
cause a pathognomonic picture, but rather one similar to 
other viral pneumonias, inflammatory pneumonitis and 
ARDS.
Perspectives
Bedside ultrasound could contribute in identifying 
COVID-19 pneumonia and guide on patient manage-
ment. Screening for signs of COVID-19 pneumonia will 
only take 3 min with an excellent negative predictive 
value, and when a 12- zone ultrasound is necessary, this 
will take 10 min after which useful information to guide 
on patient management is obtained. Also, this technique 
comes along with less exposure of healthcare personnel 
and other patients to a patient with COVID-19 because 
of its use directly at the bedside. Most importantly, 
bedside lung ultrasound can be available in resource 
constrained areas even off the grid when handheld 
ultrasound devices are used.
Limitations
This multicentre study has numerous limitations. As 
all patients were scanned using the 12- zone protocol, 
the diagnostic measures calculated in the six- points 
and eight- points protocols can be overrated. Because 
we applied a lawn mower technique, more positive 
findings were seen in the six- points protocol when 
compared with a strict adherence to the anatomical 
points described in this protocol. In our opinion, a too 
rigid adherence to exact anatomical points is a false 
interpretation and will result in a decrease in diag-
nostic accuracy, especially in a disease with a patchy and 
irregular pattern like COVID-19 pneumonia. Only one 
physician performed the lung ultrasound per patient. 
Hospital protocol did not allow the same patient to be 
scanned by three separate physicians, to minimise infec-
tion risk and to avoid unnecessary spending of scarce 
personal protection material. Since all the scanning was 
performed and recorded systematically in 12 separate 
images, we consider the influence on the classification 
of the six- points and eight- points protocols as minimal. 
Moreover, the same methodology was used in research 
to compare different ultrasound protocols in heart 
failure and deep vein thrombosis.27 35 36
The diagnostic accuracy measures found in this study 
are subject to a possible attention bias due to the high 
prevalence setting in which we performed our study. Lung 
ultrasound has an excellent negative predictive value and 
sensitivity to screen for possible COVID-19. However, we 
advocate future research on this subject in low prevalence 
setting.
In this study, we applied two reference standards for 
COVID-19: (serial) PCR (gold standard) and the final 
diagnosis. The latter was a positive decision made by an 
MDT expert based on clinical information, microbiolog-
ical, RT- PCR SARS- COV-2 and CT of the chest data. This 
approach reflects daily practice and has the advantages 
of detecting patients with COVID-19 with false negative 
RT- PCR results, and being applicable in circumstances 
where RT- PCR data are not readily available. This 
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approach is advocated by the WHO. From a method-
ological viewpoint, the comparison between a molec-
ular diagnosis of COVID-19 (RT- PCR) and imaging to 
detect COVID-19 pneumonia is an incongruence. Still, 
pneumonia and its sequalae are the majority of COVID-
19’s morbidity and mortality and thus we feel the combi-
nation suits better in day to day care. For clarity reasons, 
we reported the comparison between lung ultrasound 
and RT- PCR, and the comparison between lung ultra-
sound and MDT decision separately. The results of both 
comparisons are, respectively, listed in tables 2 and 3.
Importantly, regardless of the reference chosen, the 
findings in our study remain the same.
We have used various ultrasound systems (mostly hand-
held). Although this causes heterogeneity, it does reflect 
daily clinical practice and thus adds to the generalisability 
of our findings.
CONCLUSION
Identifying COVID-19 at the ED can be aided by bedside 
lung ultrasound. A 3- minute scan of the six lung zones 
can safely rule out COVID-19 pneumonia. The 12- zone 
scanning protocol is the only protocol that is specific 
enough to diagnose COVID-19 pneumonia at the ED 
in a high prevalence setting. We recommend further 
research be conducted in other settings to validate our 
findings.
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Appendices of Comparing Lung Ultrasound: Extensive vs Short  in COVID-19 (CLUES). 
 
Supplementary table 1: Sonographic features of COVID-19 pneumonia compared to CT 
findings, after Peng et al. [18] 
Lung ultrasound Chest CT 
Thickened & irregular pleural line Thickened pleura 
B-lines (discrete, multifocal or confluent) Ground glass opacities (GGOs)  
Confluent B-lines Pulmonary infiltrating shadow 
Sub-pleural consolidations or ‘skip’ lesions Sub-pleural consolidation 
Both non‐translobar and translobar consolidation Translobar consolidation 
Rare pleural effusion Rare pleural effusion 
Multi-zone, patchy distribution of abnormalities  Multiple lobes affected 
 
Early stage and mild infection: focal B-lines are the main feature. 
Progressive stage and severe infection: alveolar interstitial 
syndrome is the main feature. 
Convalescence: returning of A-lines are the main feature. 
Pulmonary fibrosis: pleural line thickening with uneven B lines are 
the main feature. 
Very early stage: negative or atypical findings in lung CT images. 
Pneumonia: diffuse scattered or ground glass opacities are seen. 
With progression of the disease further lung consolidation are the 
main feature.  
 
Supplementary table 2: McNemar test results. 
 
McNemar test 12-zone vs 8-points 12-zone vs 6-points 8-points vs 6-points 
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SARS-CoV-2 PCR + 0.000 0.250 0.022 
SARS-CoV-2 PCR - 0.238 0.000 0.004 
 
McNemar test 12-zone vs 8 points 12-zone vs 6-points 8-points vs 6-points 
Final diagnosis + 0.003 0.625 0.022 
Final diagnosis - 0.332 0.000 0.004 
 
Supplementary table 3: descriptive statistics of clinical symptoms. 





Fever 63 (70.0) 47 (41.6) 0.001 
Coughing 71 (78.9) 64 (56.6) 0.000 
Wheezing 2 (2.1) 0 (0.0) 0.001 
Dyspnea 60 (66.7) 52 (46.0) 0.001 
Fatigue 33 (34.4) 24 (21.2) 0.000 
Headache 15 (16.7) 14 (12.4) 0.086 
Diarrhea 17 (18.9) 7(6.2) 0.000 
Muscle pain 21 (23.3) 10 (8.8) 0.000 
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Entrustable Professional Activity (EPA).  
EPA is a key task of a discipline (e.g. acute internal medicine) that an individual can be 
trusted to perform in a given health care context, once sufficient competence has been 
demonstrated. (after ten Cate O. Entrustability of professional activities and competency-
based training. Med Educ. 2005;39(12):1176-1177. doi:10.1111/j.1365-2929.2005.02341.x)  
EPA Level 
1 Observation, no task performance.  
2 Task performance whilst receiving active supervision. 
3 Task performance with remote supervision. 
4 Independent in task performance. 
5 Independent and supervising others. 
 
Lung ultrasound performed:  242 
 89  Positive SARS-CoV-2 PCR  113 Negative SARS-CoV-2 PCR  
Lung ultrasound &SARS-CoV-2 PCR 
performed:  202 
No SARS-CoV-2 PCR  
performed: 23 
No informed consent: 10 
No complete Lung 
ultrasound: 6 
Known positive SARS-CoV-2 
PCR 1 month earlier: 1 
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